University of Texas MD Anderson Cancer Center
Custom development of MOR fluorescent ligands for receptor visualization, based on opioid structures.
Twist Biosciences
Custom development of C5aR fluorescent ligands for use in flow cytometry competition binding assays.
Nxera Pharma
Custom development of GPCR fluorescent ligands for target visualization and screening assay development.
Hawk Biosystems
Custom development of ad hoc fluorescent labeling reagents for antibody labeling, intended for biopsy sample characterization.
Boehringer Ingelheim
Validation of Celtarys GPCR fluorescent ligands in HTRF experiments.
Axxam
Collaboration on the development of screening assays to study solute carrier substrates.
G-Clips Biotech
Collaboration on the development of an integrated binding and functional assay for CXCR4 drug screening.
ZeClinics
Fluorescent probes development in the frame of AEI-Asebio project for the development of new drugs for the treatment of Parkinson’s through Artificial Intelligence and massive screening of compounds.
Lilly
Custom development of HDAC fluorescent ligands for screening assay development.
Roche
Technology assessment and feasibility study for the development of antibody labeling reagents to confirm the mechanism of action of new antibody drug candidates.
Pfizer
Validation of GPCR Celtarys fluorescent ligands in screening assays.
Arcoscreen
Collaboration in the development of fluorescent GTPgammaS for GPCR funtional assays.
University of Cambridge
Portfolio fluorescent ligands
University of California
Portfolio fluorescent ligands
University of Colorado
Portfolio fluorescent ligands
University of Exeter
Portfolio fluorescent ligands
University of Florida
Portfolio fluorescent ligands
University of Helsinki
Portfolio fluorescent ligands
University of Miami, Miller School of Medicine
Portfolio fluorescent ligands
University of Oxford
Portfolio fluorescent ligands
University of Southern Denmark
Portfolio fluorescent ligands
Vanderbilt University
Portfolio fluorescent ligands
Washington University
Portfolio fluorescent ligands
Baylor College of Medicine
Portfolio fluorescent ligands
Centre de Recherche CHUM
Portfolio fluorescent ligands
Centre Médical Universitaire Genève
Portfolio fluorescent ligands
Universidad Complutense de Madrid
Portfolio fluorescent ligands
Icahn School of Medicine
Portfolio fluorescent ligands
Indiana Biosciences Research Institute
Portfolio fluorescent ligands
Indiana University of Medicine
Portfolio fluorescent ligands
INSERM Paris
Portfolio fluorescent ligands
LMU Munich
Portfolio fluorescent ligands
Stanford University
Portfolio fluorescent ligands
The Ottawa Hospital
Portfolio fluorescent ligands
Celentyx Ltd
Portfolio fluorescent ligands
Tectonic Therapeutic, Inc
Portfolio fluorescent ligands
Our Customers
PERTE SALUD Proyecto Nº: IDI-2025-0751
Título: TERAPIAS AVANZADAS EN INMUNOONCOLOGÍA: UNA ESTRATEGIA INNOVADORA
BASADA EN LA DEGRADACIÓN DIRIGIDA DE GPCR EN EL EJE ADENOSINÉRGICOS
EIC Pathfinder; Project name: Unisens; Universal GPCR Activity Sensor for Next Generation Drug Discovery
Esta entidad fue beneficiaria de las ayudas para la ejecución de acciones de promoción exterior de las empresas gallegas. El objetivo principal de estas ayudas es incentivar la realización de acciones de promoción exterior generadoras de ventajas competitivas. El resultado que se pretende conseguir es el impulso de las pymes y sus productos y servicios, aumentando el número de empresas de base exportadora.
Celtarys Research is beneficiary of a WomenTechEU grant supporting deep-tech start-ups led by women
Principia 2021 Program
Celtarys staff has been funded by the Xunta de Galicia within the framework of the PRINCIPIA 2021 Program of the Galician Innovation Agency (GAIN)
InnovaPEME Program
Celtarys Innovation Plan has been funded by the InnovaPEME 2022 program of the Galician Innovation Agency (GAIN)
Bonos de Innovación de Celtarys Research (026)
Para promover o desenvolvemento tecnolóxico, a innovación e unha investigación de calidade. Esta operación está financiada pola Xunta de Galicia, a través de axudas concedidas pola Axencia Galega de Innovación, dentro do programa de axudas a empresa Bonos de innovación 2022.
Celtarys Research is part of the public-private consortium developing the project PREDICTEAM
New prognostic quantitative biomarker assays for predicting patient response to immune checkpoint inhibitor (ICI) treatment
NEOTEC · CDTI — Ministerio de Ciencia e Innovación
The Project ‘New chemical conjugation technology for therapeutic targets’ has been founded by CDTI under its program NEOTEC. The NEOTEC program objective is supporting the establishment and consolidation of technology-based enterprises. A technology-based company (EBT) is a company whose activity focuses on the exploitation of products or services that require the use of technologies and knowledge developed since the research activity. The EBT base their business strategy or activity in the intensive domain of scientific and technical knowledge. Budget awarded: 416.177€ | Execution dates: 1/1/2023 – 31/03/2024